Spravato costs roughly $600 to $1,100 per treatment session without insurance, depending on dose, plus a monitoring fee. Most commercial plans and Medicare cover it for treatment-resistant depression with prior authorization, and the manufacturer copay program can reduce commercially insured patients' drug cost to as little as $10 per session. Typical insured patients pay their specialist copay.
Spravato is expensive. The nasal spray devices themselves carry a list price in the hundreds of dollars per dose, each session requires two hours of monitored clinic time, and the induction phase involves eight sessions in the first month. Spravato is also, for most patients, covered. The gap between those two facts is where most of the confusion about cost comes from.
What goes into a Spravato session
Every Spravato session has two billable components.
The drug. Spravato comes in single-use nasal spray devices containing 28 mg each. A 56 mg dose uses two devices; an 84 mg dose uses three. Janssen's wholesale acquisition cost has been roughly $300 per device, so the drug alone costs about $600 for a 56 mg dose and about $900 for an 84 mg dose at list, before any negotiated discounts.
The monitoring visit. The FDA label and the REMS program require that you remain in the clinic for at least two hours after each dose, with blood pressure checks and observation by trained staff. This is billed as a separate service, with specific codes that account for the observation time. Clinic fees for this vary, roughly $150 to $400 per session.
Add the two together and a self-pay session runs roughly $750 to $1,300. The initial psychiatric evaluation before treatment is separate; at Stedfast Psychiatry a self-pay new-patient visit is $185.
The treatment schedule, which drives total cost
Spravato is given in phases, and the number of sessions determines the total.
- Induction: twice a week for four weeks, 8 sessions.
- Maintenance, weeks 5 to 8: once a week, 4 sessions.
- Maintenance, week 9 onward: once a week or once every two weeks, based on response.
A full first year, if you continue to maintenance every two weeks, involves roughly 30 to 35 sessions. Some patients taper to less frequent dosing or stop after sustained remission; others continue indefinitely.
What insurance pays
Since approval in 2019, commercial coverage of Spravato has become routine. Nearly all major plans, including Aetna, Cigna, UnitedHealthcare, Blue Cross Blue Shield plans and Humana, cover it for treatment-resistant depression with prior authorization. Medicare covers it under Part B as a physician-administered drug. Medicaid coverage exists in most states but varies by managed care plan.
The standard criteria for authorization match the FDA label: a diagnosis of major depressive disorder, failure of at least two oral antidepressants at adequate dose and duration in the current episode, concurrent use of an oral antidepressant, and treatment at a REMS-certified site. Some plans also require a documented therapy trial or a TMS trial.
Once approved, the plan pays for both the drug and the monitoring visit at contracted rates, and you pay your share according to the plan design. Because Spravato is given in a clinic, it is typically processed under your medical benefit rather than your pharmacy benefit, which means it falls under your medical deductible and coinsurance rather than a pharmacy tier copay.
The manufacturer copay program
Janssen offers a copay savings program for commercially insured patients that covers a large portion of the drug's out-of-pocket cost, bringing the patient's share of the drug down to as little as $10 per session, subject to an annual maximum. The program does not cover the monitoring fee, and it is not available to Medicare, Medicaid or other government plan members, because federal rules prohibit manufacturer copay assistance for those programs.
For patients without insurance or with a plan that denies coverage, Janssen's patient assistance foundation may provide the drug at no cost based on income. The clinic can help you apply.
Realistic cost examples
| Situation | Induction month (8 sessions) | Following year (about 26 sessions) |
|---|---|---|
| Commercial PPO, deductible met, $50 copay, copay program for drug | About $400 to $500 | About $1,300 to $1,600 |
| Commercial, $3,000 deductible not met, then 20 percent | Up to $3,000 plus coinsurance, less drug copay assistance | Coinsurance until out-of-pocket max |
| Original Medicare with Medigap Plan G | Part B deductible only | $0 beyond deductible |
| Original Medicare, no supplement | 20 percent of approved amount, about $1,200 to $1,600 | About $3,500 to $5,000, less if you hit a Medicare Advantage cap |
| Self-pay, no assistance | About $6,000 to $10,000 | About $20,000 to $34,000 |
These are illustrations. The practice verifies your specific benefits and gives you a written estimate before your first session.
Questions to ask before you start
A few questions, asked up front, prevent most billing surprises. Is the drug billed under my medical or pharmacy benefit? Has prior authorization been approved, and for how many sessions? What is the clinic's monitoring fee and what does my plan pay toward it? Am I enrolled in the copay program? What happens to my cost once I reach my out-of-pocket maximum? A clinic that can answer all five before your first session is one that has done this many times.
Some plans approve induction only and require a separate authorization for maintenance, with evidence of response. Ask whether that applies to you so the transition at week five does not come with an unexpected bill.
Why is Spravato so expensive?
Three reasons. The drug is patented and has no generic. The REMS monitoring requirement means every dose consumes two hours of clinical space and staff time. And the device-based dosing, three single-use sprayers for an 84 mg dose, carries manufacturing and distribution cost that a bottle of pills does not.
Is it worth it? For a person who has failed several antidepressants and remains significantly depressed, the economic case is reasonable: lost productivity, repeated medication trials and the risk of hospitalization all carry costs that exceed a year of Spravato for many patients. Health economic analyses have generally found Spravato cost-effective at standard thresholds when used as labeled.
How to reduce what you pay
- Use your insurance and let the clinic run prior authorization. This is the biggest lever by far.
- Enroll in the manufacturer copay program if you have commercial insurance.
- Time the start of treatment after your deductible is met, if you have a choice.
- Pay with HSA or FSA funds.
- Apply for the manufacturer's patient assistance foundation if you are uninsured or denied.
- Ask about the clinic's self-pay monitoring fee if the drug is being provided through assistance.
Spravato at Stedfast Psychiatry
We offer Spravato at our Boynton Beach, Palm Beach Gardens and Royal Palm Beach offices. Before your first session, our staff verifies your benefits, submits prior authorization with your treatment history, enrolls you in the copay program if eligible, and gives you a clear estimate. We accept most major commercial plans and Medicare.
Bottom line
Spravato's sticker price is high, roughly $750 to $1,300 per session self-pay, but most patients never pay it. With commercial insurance and the copay program, the typical cost is a specialist copay per session. With Medicare and a supplement, it can be nearly nothing. The real cost question is whether your plan approves it, and for patients who have failed two antidepressants, it usually does.
Frequently asked questions
How much does Spravato cost with insurance?
Most insured patients pay their specialist copay or coinsurance per session, commonly $30 to $75, after any deductible. Commercially insured patients can enroll in the manufacturer copay program, which reduces the drug portion to as little as $10 per session.
How much does Spravato cost without insurance?
Roughly $750 to $1,300 per session, combining the drug (about $600 for 56 mg or $900 for 84 mg at list price) and the two-hour monitoring visit. An induction month of eight sessions can approach $10,000. The manufacturer's patient assistance foundation may provide the drug free to eligible uninsured patients.
Does the Spravato copay card work with Medicare?
No. Federal rules prohibit manufacturer copay assistance for Medicare and Medicaid patients. Medicare covers Spravato under Part B, and a Medigap supplement or Medicare Advantage plan limits what you owe.
Why does Spravato cost more than ketamine infusions per session?
Spravato is a patented, branded drug with mandatory two-hour monitoring; IV ketamine is a generic anesthetic used off-label. However, insurance covers Spravato and rarely covers IV ketamine, so for insured patients Spravato is usually far cheaper out of pocket.
Related reading
- Does Medicare Cover Spravato?
- How Prior Authorization Works for TMS and Spravato
- Spravato vs Ketamine Infusions: An Honest Comparison
- How Much Does TMS Cost With and Without Insurance?
This article is educational and does not replace evaluation by a licensed clinician. If you are in crisis, call or text 988.